Lemtrada (alemtuzumab) should be restricted to people with highly active relapsing remitting MS according to a review carried out by the European Medicines Agency's (EMA) drug safety committee.
Highly active relapsing remitting MS covers people who continue to have relapses despite taking at least one disease modifying drug (DMD) or if MS is worsening rapidly with at least two disabling relapses in a year and MRI scans show new MS activity. In addition, Lemtrada must no longer be used in people with certain heart, circulation or bleeding disorders or in people who have auto-immune disorders other than MS.
The recommendations also include new measures to identify and treat problems that may occur after having a Lemtrada infusion.
Earlier this year, the EMA began their review of Lemtrada following reports of side effects affecting the heart, blood vessels, liver and immune system. These side effects are rare but potentially serious. While the review was being carried out, Lemtrada use was restricted to people with relapsing remitting MS that continued to be very active despite taking at least two disease modifying drugs.
Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 Feb 2021 - 00:00
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.
Exercise is good for your brain
3 Feb 2021 - 00:00
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.
Covid-19 vaccines and MS: Part two
29 Jan 2021 - 00:00
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.
Receiving an MS diagnosis during my gender transition
22 Feb 2021 - 00:00
Chris shares his experience of being diagnosed with MS at the same time as starting hormone treatment and a surgical gender transition.
David's Diary- Should we all be saying yes to the Covid 19 vaccine?
18 Feb 2021 - 00:00
For the last few weeks our Enquiry Service at the MS Trust has been busy with questions about the vaccination. In his latest blog piece for the MS Trust, CEO David Martin asks the question, 'Should we all be saying yes to the Covid 19 vaccine?'
Monkey sox are back!
17 Feb 2021 - 00:00
...but this time they've gone casual! We are very excited to have partnered once again with Monkey Sox to bring you an exclusive MS Trust design.